Please ensure Javascript is enabled for purposes of website accessibility

A Post-Holiday Breakup ... of Sorts

By Brian Orelli, PhD - Updated Apr 5, 2017 at 7:51PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Abbott and Celera revise their partnership.

With personalized medicine on the horizon, the use of molecular diagnostic tests is sure to rise. It looks like Abbott Labs (NYSE:ABT) and Celera (NASDAQ:CRA) figure they're better off developing those tests on their own rather than continuing to team up; the companies have modified their six-year-old partnership to nix the research and development portion of the agreement.

The press release was light on the details -- no numbers were given on the royalties that will be flying in either direction on sales of the companies' m2000 real-time PCR diagnostic system and Celera's genetic tests -- so it's a little hard to see if there's a clear winner in the revision. What is clear is that the companies wanted more flexibility to develop tests for the m2000 on their own.

Part of the issue may be that Abbott now has an infectious disease instrument after its recent purchase of Ibis from Isis Pharmaceuticals (NASDAQ:ISIS). The increased flexibility gives Abbott the choice of developing new tests on whichever platform it thinks is most suitable instead of having to fight with Celera about where to spend its R&D dollars.

When Celera split from Applera, which was renamed Applied Biosystems earlier this year, I figured it would be Celera that would get snatched up -- probably by Abbott. General Electric's (NYSE:GE) health care segment could also have been a suitor. Instead Abbott went with Ibis and it was Applied Biosystems that got acquired by Invitrogen (now Life Technologies (NASDAQ:LIFE)), probably to the dismay of Roche and Illumina (NASDAQ:ILMN). Those two now have a larger foe to fight in the next-generation sequencer arena.

Celera could still get acquired, but at this point it seems more likely it'll continue the development of genetic tests on its own. Considering the coming boom, I'm not sure that's a bad place to be.

Get Foolish in 2009:

Illumina is an active Stock Advisor pick. Let Fool co-founders David and Tom Gardner show you their top stock picks absolutely free with a 30-day trial.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
$110.55 (-1.32%) $-1.48
General Electric Company Stock Quote
General Electric Company
GE
$79.92 (-1.42%) $-1.15
Ionis Pharmaceuticals, Inc. Stock Quote
Ionis Pharmaceuticals, Inc.
IONS
$43.88 (-0.99%) $0.44
Illumina, Inc. Stock Quote
Illumina, Inc.
ILMN
$213.02 (-3.10%) $-6.81

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
402%
 
S&P 500 Returns
129%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.